Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety
- PMID: 21083925
- PMCID: PMC2994872
- DOI: 10.1186/1748-717X-5-109
Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety
Abstract
Object: To assess the effects of radiosurgery (RS) on the radiological and hormonal control and its toxicity in the treatment of pituitary adenomas.
Methods: Retrospective analysis of 42 patients out of the first 48 consecutive patients with pituitary adenomas treated with RS between 1999 and 2008 with a 6 months minimum follow-up. RS was delivered with Gamma Knife as a primary or adjuvant treatment. There were 14 patients with non-secretory adenomas and, among functioning adenomas, 9 were prolactinomas, 9 were adrenocorticotropic hormone-secreting and 10 were growth hormone-secreting tumors. Hormonal control was defined as hormonal response (decline of more than 50% from the pre-RS levels) and hormonal normalization. Radiological control was defined as stasis or shrinkage of the tumor. Hypopituitarism and visual deficit were the morbidity outcomes. Hypopituitarism was defined as the initiation of any hormone replacement therapy and visual deficit as loss of visual acuity or visual field after RS.
Results: The median follow-up was 42 months (6-109 months). The median dose was 12,5 Gy (9 - 15 Gy) and 20 Gy (12 - 28 Gy) for non-secretory and secretory adenomas, respectively. Tumor growth was controlled in 98% (41 in 42) of the cases and tumor shrinkage occurred in 10% (4 in 42) of the cases. The 3-year actuarial rate of hormonal control and normalization were 62,4% and 37,6%, respectively, and the 5-year actuarial rate were 81,2% and 55,4%, respectively. The median latency period for hormonal control and normalization was, respectively, 15 and 18 months. On univariate analysis, there were no relationships between median dose or tumoral volume and hormonal control or normalization. There were no patients with visual deficit and 1 patient had hypopituitarism after RS.
Conclusions: RS is an effective and safe therapeutic option in the management of selected patients with pituitary adenomas. The short latency of the radiation response, the highly acceptable radiological and hormonal control and absence of complications at this early follow-up are consistent with literature.
Figures
Similar articles
-
Efficacy and safety of higher dose stereotactic radiosurgery for functional pituitary adenomas: a preliminary report.World Neurosurg. 2014 Jul-Aug;82(1-2):195-201. doi: 10.1016/j.wneu.2013.01.127. Epub 2013 Feb 4. World Neurosurg. 2014. PMID: 23385448
-
Gamma knife radiosurgery for pituitary adenoma: early results.Neurosurgery. 2003 Jul;53(1):51-9; discussion 59-61. doi: 10.1227/01.neu.0000068702.00330.47. Neurosurgery. 2003. PMID: 12823873
-
MASEP gamma knife radiosurgery for secretory pituitary adenomas: experience in 347 consecutive cases.J Exp Clin Cancer Res. 2009 Mar 11;28(1):36. doi: 10.1186/1756-9966-28-36. J Exp Clin Cancer Res. 2009. PMID: 19284583 Free PMC article.
-
Stereotactic radiosurgery of pituitary adenomas.Neurosurg Clin N Am. 2013 Oct;24(4):509-19. doi: 10.1016/j.nec.2013.05.005. Epub 2013 Jul 1. Neurosurg Clin N Am. 2013. PMID: 24093569 Review.
-
Stereotactic radiosurgery/radiotherapy for pituitary adenomas: a review of recent literature.Neurol Med Chir (Tokyo). 2010;50(9):749-55. doi: 10.2176/nmc.50.749. Neurol Med Chir (Tokyo). 2010. PMID: 20885109 Review.
Cited by
-
Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.Front Endocrinol (Lausanne). 2020 Aug 4;11:527. doi: 10.3389/fendo.2020.00527. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32849307 Free PMC article.
-
Fully automated imaging protocol independent system for pituitary adenoma segmentation: a convolutional neural network-based model on sparsely annotated MRI.Neurosurg Rev. 2023 May 10;46(1):116. doi: 10.1007/s10143-023-02014-3. Neurosurg Rev. 2023. PMID: 37162632
-
Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.J Neurosurg. 2018 Sep;129(3):648-657. doi: 10.3171/2017.5.JNS163069. Epub 2017 Oct 27. J Neurosurg. 2018. PMID: 29076785 Free PMC article.
-
Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.J Neurooncol. 2014 Sep;119(3):513-29. doi: 10.1007/s11060-014-1501-7. Epub 2014 Aug 14. J Neurooncol. 2014. PMID: 25119001 Review.
-
Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy.J Neurooncol. 2014 May;117(3):445-57. doi: 10.1007/s11060-013-1262-8. J Neurooncol. 2014. PMID: 24122025 Review.
References
-
- Sheehan JP, Niranjan A, Sheehan JM, Jane JA Jr, Laws ER, Kondziolka D. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg. 2005;102:678–691. doi: 10.3171/jns.2005.102.4.0678. - DOI - PubMed
-
- [IRSA] International Radiosurgery Association. Stereotactic radiosurgery for patients with pituitary adenomas. [monograph on the Internet] Harrisburg (PA) 2004. http://www.irsa.org/Pituitary%20Guideline.pdf [Accessed 13 June 2010]
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical